In vivo fluorescence flow cytometry reveals that the nanoparticle tumor vaccine OVA@HA-PEI effectively clears circulating tumor cells  

作　　者：Wei Jin Yuting Fu Sisi Ge Han Sun Kai Pang Xunbin Wei 

机构地区：[1]The Department of Biomedical Engineering Institute of Advanced Clinical Medicine,Peking University Beijing 100191,P.R.China [2]Institute of Medical Technology Peking University Health Science Center Beijing 100191,P.R.China [3]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Peking University Cancer Hospital&Institute,Beijing 100142,P.R.China [4]School of Instrument Science and Opto-Electronics Engineering Beijing Information Science&Technology University Beijing 100192,P.R.China

出　　处：《Journal of Innovative Optical Health Sciences》2024年第6期107-123,共17页创新光学健康科学杂志（英文）

基　　金：supported by the National Key Research and Development Program of China,Grant Number:2021YFF0502900,2019YFC1604604;National Natural Science Foundation of China,Grant Number:62075013,62027824.

摘　　要：Tumor vaccine therapy offers significant advantages over conventional treatments,including reduced toxic side effects.However,it currently functions primarily as an adjuvant treatment modality in clinical oncology due to limitations in tumor antigen selection and delivery methods.Tumor vaccines often fail to elicit a sufficiently robust immune response against progressive tumors,thereby limiting their clinical efficacy.In this study,we developed a nanoparticle-based tumor vaccine,OVA@HA-PEI,utilizing ovalbumin(OVA)as the presenting antigen and hyaluronic acid(HA)and polyethyleneimine(PEI)as adjuvants and carriers.This formulation significantly enhanced the proliferation of immune cells and cytokines,such as CD3,CD8,interferon-,and tumor necrosis factor-,in vivo,effectively activating an immune response against B16–F10 tumors.In vivofluorescenceflow cytometry(IVFC)has already become an effective method for monitoring circulating tumor cells(CTCs)due to its direct,noninvasive,and long-term detection capabilities.Our study utilized a laboratory-constructed IVFC system to monitor the immune processes induced by the OVA@HA-PEI tumor vaccine and an anti-programmed death-1(PD-1)antibody.The results demonstrated that the combined treatment of OVA@HA-PEI and anti-PD-1 antibody significantly improved the survival time of mice compared to anti-PD-1 antibody treatment alone.Additionally,this combination therapy substantially reduced the number of CTCs in vivo,increased the clearance rate of CTCs by the immune system,and slowed tumor progression.Thesefindings greatly enhance the clinical application prospects of IVFC and tumor vaccines.

关 键 词：Tumor vaccines circulating tumor cells in vivo fluorescence flow cytometry. 

分 类 号：R73[医药卫生—肿瘤]